Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 798
- Registration Number
- NCT00738153
Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 314
- Registration Number
- NCT00735501
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 243
- Registration Number
- NCT00729898
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Farsta, Sweden
Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT00728455
Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 305
- Registration Number
- NCT00725036
- Locations
- 🇦🇺
Novo Nordisk Investigational Site, Stones Corner, Australia
Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT00722540
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 342
- Registration Number
- NCT00715351
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1667
- Registration Number
- NCT00715780
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00715689
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1584
- Registration Number
- NCT00715663
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
© Copyright 2024. All Rights Reserved by MedPath